Intact SMAD-4 is a predictor of increased locoregional recurrence in upfront resected pancreas cancer receiving adjuvant therapy Article

publication date

  • June 8, 2021

webpage

published in

keywords

  • Pancreas cancer
  • chemoradiotherapy (CRT)
  • mothers against decapentaplegic homolog 4 (SMAD4)
  • patterns of recurrence
  • tissue microarray (TMA)